MTOR and melanoma: Our previous research results (Ciołczyk-Wierzbicka et al. 2019) confirmed that the nanomolar concentration of the mTOR everolimus inhibitor in combination with the MEK1/2 inhibitor AS-703026 was effective in activating caspase 3 activity and the apoptosis process in the WM115 and WM266-4 melanoma cell lines.